Vaccine Options Available To Protect Against COVID-19

While most of us traditionally receive our annual flu shot during the fall “immunization season,” we also need to be mindful of the post-pandemic world in which we live and consider the need to protect ourselves from COVID-19. The updated 2024-2025 Novavax COVID-19 vaccine is now available. Help protect yourselves and your loved ones this cold and flu season.

When selecting a COVID vaccine, there are different options available – mRNA and protein-based non-mRNA vaccines. The mRNA vaccines, developed by Pfizer and Moderna, teach our cells how to make copies of the spike protein which triggers an immune response. The non-mRNA protein-based vaccine, developed by Novavax, uses protein fragments of the virus that causes COVID-19 along with an ingredient called an adjuvant to help the immune system respond to the spike protein in the future.

According to the CDC, it is safe to receive both COVID-19 and flu vaccines during the same visit. However, be sure to ask your healthcare provider about your vaccine options, including adding a COVID-19 vaccine to your appointment if you’re already planning to get a flu shot.

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-19 in individuals aged 12 and older are in stock at major pharmacy retailers across the U.S.

Through agreements with pharmacies, Novavax’s updated vaccine is widely available in locations including, but not limited to, CVS Pharmacy, Rite Aid, Walgreens, Costco, and hundreds of other regional grocers and thousands of independent pharmacies. Novavax’s updated vaccine received Emergency Use Authorization (EUA) on August 30, 2024 from the U.S. Food and Drug Administration (FDA).

"We have worked hard to ensure greater ease of access for consumers this vaccination season by more than doubling the number of locations stocking our vaccine compared to last year and offering a more convenient presentation in a pre-filled syringe," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Our vaccine targets JN.1, the ‘parent strain’ of those currently circulating, and our vaccine has demonstrated cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1.1"

Novavax’s vaccine is the only protein-based option available in the U.S. this fall and is in pre-filled syringe presentation. Doses of Novavax's vaccine can be located on us.novavaxcovidvaccine.com. Learn more by visiting us.novavaxcovidvaccine.com or vaccines.gov.